Viking Therapeutics (VKTX:NGS) — FY’17 Q3 Quarterly Update

— — — — —

Viking Therapeutics (VKTX) reported Q3’17 results on Nov-8th after market-hours. Headline results showed a slight earnings “miss” in the quarter as a result of a non-cash charge, however this remains essentially irrelevant in context of both the near-term and long-term investment thesis as the company awaits the release of top-line data from its phase II trial on molecule VK5211. Shares have essentially traded flat since the quarterly release in the $2.20 range; and while this is down materially from the $3+ price level achieved in mid-October, is still higher by ~100% from the summer months…






— — —

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s